A Rare but Treatable Disease: Therapeutic Considerations for Hairy Cell Leukemia

Published: Wednesday, Jul 10, 2019
 Martin S. Tallman, MD

Martin S. Tallman, MD
While uncommon, the prognosis for hairy cell leukemia (HCL) is quite favorable, explains Martin S. Tallman, MD, adding that most patients respond to the standard of care, cladribine, with relapse rates between 25% and 35%.

However, as the biology of HCL continues to be further understood, markers such as BRAF mutations has opened the door to new therapeutic strategies for patients.

In an interview with OncLive, Tallman, c
hief of Leukemia Service, Cassidy Family Endowed Faculty Chair, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the biology, prognosis, and current treatment options available in HCL.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x